These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 12857935)

  • 21. Protective effects of St. John's wort extract and its component hyperforin against cytokine-induced cytotoxicity in a pancreatic beta-cell line.
    Menegazzi M; Novelli M; Beffy P; D'Aleo V; Tedeschi E; Lupi R; Zoratti E; Marchetti P; Suzuki H; Masiello P
    Int J Biochem Cell Biol; 2008; 40(8):1509-21. PubMed ID: 18226577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
    Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
    Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues.
    Matheny CJ; Ali RY; Yang X; Pollack GM
    Drug Metab Dispos; 2004 Sep; 32(9):1008-14. PubMed ID: 15319343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperforin-containing extracts of St John's wort fail to alter gene transcription in brain areas involved in HPA axis control in a long-term treatment regimen in rats.
    Butterweck V; Winterhoff H; Herkenham M
    Neuropsychopharmacology; 2003 Dec; 28(12):2160-8. PubMed ID: 12865894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
    Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
    Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical anti-inflammatory activity of extracts and compounds from Hypericum perforatum L.
    Sosa S; Pace R; Bornancin A; Morazzoni P; Riva A; Tubaro A; Della Loggia R
    J Pharm Pharmacol; 2007 May; 59(5):703-9. PubMed ID: 17524236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of Saint John's Wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6beta-hydroxycortisol in healthy volunteers.
    Bauer S; Störmer E; Kerb R; Johne A; Brockmöller J; Roots I
    Eur J Clin Pharmacol; 2002 Dec; 58(9):581-5. PubMed ID: 12483450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts.
    Onoue S; Seto Y; Ochi M; Inoue R; Ito H; Hatano T; Yamada S
    Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction.
    Mai I; Bauer S; Perloff ES; Johne A; Uehleke B; Frank B; Budde K; Roots I
    Clin Pharmacol Ther; 2004 Oct; 76(4):330-40. PubMed ID: 15470332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The interaction between St John's wort and an oral contraceptive.
    Hall SD; Wang Z; Huang SM; Hamman MA; Vasavada N; Adigun AQ; Hilligoss JK; Miller M; Gorski JC
    Clin Pharmacol Ther; 2003 Dec; 74(6):525-35. PubMed ID: 14663455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of hyperforin in the pharmacological activities of St. John's Wort.
    Zanoli P
    CNS Drug Rev; 2004; 10(3):203-18. PubMed ID: 15492771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperforin modifies neuronal membrane properties in vivo.
    Eckert GP; Keller JH; Jourdan C; Karas M; Volmer DA; Schubert-Zsilavecz M; Müller WE
    Neurosci Lett; 2004 Sep; 367(2):139-43. PubMed ID: 15331138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute and chronic actions of a dry methanolic extract of Hypericum perforatum and a hyperforin-rich extract on dopaminergic and serotonergic neurones in rat nucleus accumbens.
    Rommelspacher H; Siemanowitz B; Mannel M
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S119-26. PubMed ID: 11518060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
    Laakmann G; Schüle C; Baghai T; Kieser M
    Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():54-9. PubMed ID: 9684948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
    Schulz HU; Schürer M; Bässler D; Weiser D
    Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse.
    Bray BJ; Brennan NJ; Perry NB; Menkes DB; Rosengren RJ
    Life Sci; 2002 Feb; 70(11):1325-35. PubMed ID: 11883710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.
    Wurglics M; Schubert-Zsilavecz M
    Clin Pharmacokinet; 2006; 45(5):449-68. PubMed ID: 16640452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells.
    Schempp CM; Winghofer B; Lüdtke R; Simon-Haarhaus B; Schöpf E; Simon JC
    Br J Dermatol; 2000 May; 142(5):979-84. PubMed ID: 10809859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of ethanol intake by chronic treatment with Hypericum perforatum, alone or combined with naltrexone in rats.
    Perfumi M; Mattioli L; Cucculelli M; Massi M
    J Psychopharmacol; 2005 Sep; 19(5):448-54. PubMed ID: 16166181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.